TORONTO, June 10, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable ...
BOSTON and YOKNEAM, Israel, April 22, 2025 /PRNewswire/ -- Butterfly Medical, a medical device company focused on alleviating suffering in patients with BPH (Benign Prostatic Hyperplasia), announced ...
TORONTO, Nov. 28, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets AI-powered, ...
Transurethral resection of the prostate (TURP) is a medical procedure that may help treat benign prostatic hyperplasia (BPH). Medicare covers TURP for people who meet their requirements. Yes, Medicare ...
Profound Medical Corp. (NASDAQ:PROF) is one of the best Canadian stocks with huge upside potential. On June 10, Profound Medical announced the successful completion of the first commercial benign ...
The goals of therapy for BPH are to ameliorate LUTS, prevent related complications, and achieve measurable improvement in the patient's QOL. 3 In addition to drug and resource utilization costs, ...
TORONTO, Nov. 28, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets AI-powered, ...
New BPH module and clinical data reinforce the TULSA Procedure™’s versatility in prostate disease, superior patient benefits, and potential for mainstream adoption TORONTO, Nov. 28, 2025 (GLOBE ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback